home.aspx

 
. home.aspx home.aspx

ARCHIVED NEWS


    BIOLOGICAL CRUISE CONTROL ENGINEERED INTO LIVING CELLS

    Jun 20, 2019

    Cars have cruise control. Jet planes have auto pilot. Factories have industrial process control. And now, thanks to synthetic biology, cells have human-engineered integral feedback control. In a proof-of-concept study, Escherichia coli bacteria have been equipped with a controller in the form of a c...


    READ MORE

    /news-article.aspx?ID=32913291

    STEM CELL COMPANY PERSUADES EMPLOYERS TO STEER WORKERS TOWARD CONTROVERSIAL THERAPY

    Jun 20, 2019

    A Midwestern grocery chain, Hy-Vee, is taking an unusual — and highly controversial — approach to reducing health care costs. Before employees in certain cities can undergo knee replacement, they first must visit a stem cell provider. Hy-Vee has contracted with one of the United States&r...


    READ MORE

    /news-article.aspx?ID=32923292

    WHY CLIMATE CHANGE MEANS A RETHINK OF COFFEE AND COCOA PRODUCTION SYSTEMS

    Jun 20, 2019

    Global demand for coffee and cocoa is on the rise. Yet across the equatorial belt where these two crops are produced, the future is not looking bright. Climate change in the tropics is pushing coffee and cocoa closer to the limits of physiological tolerance and constraining the places where they can...


    READ MORE

    /news-article.aspx?ID=32933293

    DNA MICROSCOPY OFFERS ENTIRELY NEW WAY TO IMAGE CELLS

    Jun 20, 2019

    Microscopy just got reinvented again. Traditionally, scientists have used light, x-rays, and electrons to peer inside tissues and cells. Today, scientists can trace thread-like fibers of nerves throughout the brain and even watch living mouse embryos conjure the beating cells of a rudimentary heart....


    READ MORE

    /news-article.aspx?ID=32943294

    SANOFI TO AX 466 JOBS, STEP UP FOCUS ON CANCER, GENE THERAPY R&D

    Jun 20, 2019

    Sanofi is to cut 466 jobs in France and Germany as part of the reorganization of its R and D group. The job losses are part of a pivot away from cardiovascular diseases and toward immuno-oncology drugs and gene therapies. In recent years, Sanofi has sought to revitalize its R&D group, making cha...


    READ MORE

    /news-article.aspx?ID=32953295

    NEWLY IDENTIFIED APPETITE-CONTROLLING NEURAL CIRCUIT RESPONDS TO FOOD SMELLS

    Jun 19, 2019

    Studies in mice by a Baylor College of Medicine-led team have identified a previously unknown neural circuit that is activated by food odors and stops the animals from eating, to the point that they starve to death. The researchers say further studies will be needed to determine whether the same cir...


    READ MORE

    /news-article.aspx?ID=32863286

    A UNIVERSAL CONTROL SYSTEM FOR SYNTHETIC GENE NETWORKS

    Jun 19, 2019

    Anyone who has lived without central heating and cooling has had to learn the right combinations of opening windows, turning on radiators or adjusting blinds to get the temperature just right. Modern thermostats eliminate all that: you set them once and the built-in controllers do the rest, regardle...


    READ MORE

    /news-article.aspx?ID=32873287

    FDA CLEARS J&J AND GRIFOLS’ BLOOD-STOPPING PROTEIN SPRAY FOR SURGICAL BLEEDS

    Jun 19, 2019

    Johnson and Johnsons Ethicon unit has received a 510(k) clearance from the FDA for its Vistaseal applicators, which spray a biological sealant to stem moderate bleeding during open or laparoscopic surgical procedures. The airless spray products are the first fruit of a broad partnership between the ...


    READ MORE

    /news-article.aspx?ID=32883288

TRENDING NEWS


    RESEARCHERS DISCOVER GENOME-WIDE VARIATIONS IN GENE EXPRESSION BETWEEN MALE AND FEMALE MAMMALS

    Jul 19, 2019

    A team of researchers affiliated with several institutions in the U.S. has discovered genome-wide variations in gene expression between male and female mammals. In their paper published in the journal Science, the group describes their RNA sequencing studies in several types of mammals and what they...

    PHYS.ORG
    READ MORE

    /news-article.aspx?ID=34083408

    NEWLY DISCOVERED BIOSYNTHETIC PATHWAY IN BACTERIA RECIPE FOR DRUG DISCOVERY AND PRODUCTION

    Jul 19, 2019

    Microbes are master chefs of the biomolecular world; collectively, they harbor the ability to produce a vast array of unknown substances, some of which may have therapeutic or other useful properties. In searching for useful products, a team of chemists at Illinois have discovered a whole new class ...

    PHYS.ORG
    READ MORE

    /news-article.aspx?ID=34093409

    HELPING ROBOTS TO BUILD NEW ANTIBIOTICS

    Jul 19, 2019

    A team from The University of Manchester have engineered a common gut bacterium to produce a new class of antibiotics by using robotics. These antibiotics, known as class II polyketides, are also naturally produced by soil bacteria and have antimicrobial properties which are vital in the modern phar...

    PHYS.ORG
    READ MORE

    /news-article.aspx?ID=34103410

    SCIENTISTS DISCOVER GROUP OF GENES CONNECTED TO LONGER LIFE IN FRUIT FLIES

    Jul 19, 2019

    Alexey Moskalev, Ph.D., Head of the Laboratory of Geroprotective and Radioprotective technologies and co-authors from the Institute of biology of Komi Science Center of RAS, the Engelgard's Institute of molecular biology of RAS and Moscow Institute of Physics and Technology published an article ...

    PHYS.ORG
    READ MORE

    /news-article.aspx?ID=34113411

    LOOKING FOR OFEV FOLLOW-UP, BOEHRINGER PICKS UP BRIDGE BIOTHERAPEUTICS' IPF MED FOR $50M

    Jul 19, 2019

    Nearly five years after lung-scarring med Ofev got the FDA nod, its maker wants to get cracking on a  successor. Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million ($50 million) upfront. Seongnam, South Korea-based Bridge Biotherapeutics is...

    FIERCEBIOTECH
    READ MORE

    /news-article.aspx?ID=34123412

    DNA ORIGAMI JOINS FORCES WITH MOLECULAR MOTORS TO BUILD NANOSCALE MACHINES

    Jul 18, 2019

    For decades, researchers have chased ways to study biological machines. Every mechanical movement  from contracting a muscle to replicating DNA  relies on molecular motors that take near-undetectable steps. Trying to see them move is like trying to watch a soccer game taking place on the m...


    READ MORE

    /news-article.aspx?ID=34043404

    LOOKING FOR OFEV FOLLOW-UP, BOEHRINGER PICKS UP BRIDGE BIOTHERAPEUTICS IPF MED FOR 50M DOLLARS

    Jul 18, 2019

    Nearly five years after lung-scarring med Ofev got the FDA nod, its maker wants to get cracking on a  successor. Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for 45 million Euros (50 million dollars) upfront. Seongnam, South Korea-based Bridge Biotherapeu...


    READ MORE

    /news-article.aspx?ID=34053405

    TORNADOES, WINDSTORMS PAVE WAY FOR LASTING PLANT INVASIONS

    Jul 18, 2019

    When tornadoes touch down, we brace for news of property damage, injuries, and loss of life, but the high-speed wind storms wreak environmental havoc, too. They can cut through massive swaths of forest, destroying trees and wildlife habitat, and opening up opportunities for invasive species to gain ...


    READ MORE

    /news-article.aspx?ID=34063406

    NEW SPECIES OF FLYING SQUIRREL FROM SOUTHWEST CHINA ADDED TO THE RAREST AND MOST WANTED

    Jul 18, 2019

    Described in 1981, the genus Biswamoyopterus is regarded as the most mysterious and rarest amongst all flying squirrels. It comprises two large 1.4-1.8 kg species endemic to southern Asia  the Namdapha flying squirrel (India) and the Laotian giant flying squirrel (Lao PDR). Each is only known f...


    READ MORE

    /news-article.aspx?ID=34073407

    ASTELLAS PICKS UP FREQUENCYS REGENERATIVE HEARING LOSS MED OUTSIDE U.S. FOR 80M DOLLARS

    Jul 17, 2019

    After its hearing loss treatment proved itself safe in a small phase 1 study, Frequency Therapeutics is calling in reinforcements to help it cross the finish line. The company is licensing the program to Astellas Pharma, which will develop and market the drug outside the U.S., for $80 million upfron...


    READ MORE

    /news-article.aspx?ID=33993399

    INOVIO AXES STAFFERS, CANCER PROGRAM TO SHARPEN FOCUS, SAVE CASH

    Jul 17, 2019

    A few months after AstraZenecas MedImmune unit walked away from some of its R and D work with the biotech, Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a cancer program. Back in May, and coming from a brief Securities and Exchange Commission update, the biotech said:...


    READ MORE

    /news-article.aspx?ID=34003400

    THE LOSS OF BIODIVERSITY COMES AT A PRICE

    Jul 17, 2019

    Almost 300,000 Euros is what the Donana fire cost in terms of biodiversity, according to an estimate done by a University of Cordoba research group. The fire occurred in 2017 and destroyed about 8,500 hectares, most of which were part of Doñana National Park, home to a number of emblematic sp...


    READ MORE

    /news-article.aspx?ID=34013401

SPOTLIGHT

At Amgen, we believe in a “biology first” approach. We use cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from diseases. Amgen believes the cure for disease can be found inside each an

RESOURCES

Events